Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Alan David Swinamer

Ming-Hong Hao

Pier Francesco Cirillo

Derek Cogan

John Robert Proudfoot

Daniel Kuzmich

Steffen Breitfelder

Can Mao

John R Regan

Hidenori Takahashi

Hossein Razavi

Usha R Patel

Thomas A Gilmore

Victor Marc Kamhi

Kevin Chungeng Qian

Eugene R Hickey

Daniel R Goldberg

David S Thomson

Neil Moss

Christopher Ronald Sarko

Zhaoming Xiong

Donghong Amy Gao

Matthew Russell Netherton

Brian Nicholas Cook

Pingrong Liu

Zhulin Tan

John Lord

Craig Andrew Miller

Darren DiSalvo

Rajiv Sharma

Christian Harcken

Brian Christopher Raudenbush

Thomas Wai-ho Lee

Jochen Neu

Sanxing Sun

Roger John Snow

Jinhua Jeff Song

Abdelhakim Hammach

Jiang-Ping Wu

Qiang Zhang

Jonathan Timothy Reeves

Alexander Heim-Riether

Ingo Andreas Mugge

Ronald A Aungst, Jr

Darren Todd Disalvo

Gregory Paul Roth

Daniel Robert Fandrick

Rajashehar Betageri

Paul S Riska

Thomas M Kirrane

Kaka Dey

Yu Yang

Darren Di Salvo

Monica H Moriak

Brian Andrew Walter

Roger Dinallo

John Edward Mangette

Thomas Wai-Ho Lee

The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein Rto R, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

CCR10 antagonists

Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Indazole compounds as CCR1 receptor antagonists

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.  Also disclosed are methods of making and methods of using same.

Azaindazole compounds as CCR1 receptor antagonists

Disclosed are compounds of formula (I)  Where Ar, X, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Disclosed are amide compounds of formula (I): wherein Ar, Q, Y and R-Rof formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases

Disclosed compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Anti-cytokine heterocyclic compounds

Disclosed are compounds of formula (I) The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and the pharmaceutical compositions comprising these compounds.

Disclosed are compounds of formula (I) Where Ar, X, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are and pharmaceutical compositions containing, intermediate compounds and processes of making such compounds.

Intermediate arylamine compounds

Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

Compounds useful as anti-inflammatory agents

Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar ,Ar ,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Aromatic heterocyclic compounds as antiinflammatory agents

Growing community of inventors

Southbury, CT, United States of America

Alan David Swinamer